Dr. Otazo directs the MRI physics program, which includes development and translation of new MRI technology, and support for the clinical MRI program in Radiology and Radiation Oncology. His research work is focused to the development of rapid, motion-tolerant, and quantitative MRI methods using advances in mathematical, physical, and computational models. Dr. Otazo is one of the pioneers in the use of compressed sensing to accelerate MRI acquisition and a world-leader in the development of motion-tolerant MRI techniques using autonavigated acquisitions. He is currently working on the application of artificial intelligence techniques to accelerate and enable motion-tolerant MRI scans. He is also developing MRI techniques to guide radiotherapy procedures on a MR-Linac system. Dr. Otazo is a fellow of the International Society for Magnetic Resonance in Medicine and a distinguished investigator of the Academy for Radiology and Biomedical Imaging Research.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Ricardo Otazo discloses the following relationships and financial interests:
-
NYU Langone Health
Intellectual Property Rights
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures